'I just want to watch my daughter grow up': Mother's heartbreaking plea for breast cancer wonder drug Enhurtu being denied to women on the NHS, as new data shows it boosts survival by more than a third READ MORE: New guidelines do not always class terminal cancer as 'severe' By Kate Pickles Health Editor For The Daily Mail In Chicago Published: 16:51, 3 June 2024 | Updated: 16:51, 3 June 2024 e-mail 9 shares 3 View comments A drug being denied to thousands of women with incurable breast cancer could boost survival time by more than a third, new research suggests. The latest trial results found Enhertu slashed the chances of terminal breast cancer growing or spreading by 38 per cent compared to standard chemotherapy. Charities and campaigners said the new findings add to the sense of 'betrayal and disbelief' that they cannot get it on the NHS in England when it is available in Scotland.
It follows a decision by NICE in March to deny the 'wonder drug' on cost grounds using new criteria which does not class all terminal cancers as 'severe'. Women with HER2-low or ultralow breast cancer lived without their cancer growing for an average of 13.2 months, compared to just 8.
1 months among those who had chemotherapy. Sophie Blake, 51, from Brighton, was diagnosed with breast cancer in December 2020 before being told it had spread elsewhere, including to her lungs and liver in May 2022. Sophie, pictured with her daughter Maya, 17, a student at music college, said: 'I want to watch my d.
